Lead Product(s) : ASC41,ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC43F (ASC41) is a one-pill, once-a-day fixed-dose combination (FDC) for NASH treatment, thus will improve patient compliance,also showed good tolerability and safety profiles, and pharmacokinetics.
Product Name : ASC41
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : ASC41,ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ECC0509
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
Details : The trial is a Phase 1, randomized, double-blind, placebo-controlled, sequential single- and multiple ascending dose clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics of ECC0509 in healthy volunteers.
Product Name : ECC0509
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2021
Lead Product(s) : ECC0509
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication
Details : ASC42 is an in-house developed, novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. ASC42 is an oral tablet formulation developed with in-house proprietary technology and is stable at room temperature f...
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC42 is a novel non-steroidal, selective, potent FXR agonist with best-in-class potential. Gannex announced positive topline results of safety and pharmacodynamic biomarkers from the U.S. Phase I trial of ASC42 where there was no pruritus observed durin...
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2021
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Sciwind's Investigational New Drug Approved for NASH Trial
Details : XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
February 28, 2021
Lead Product(s) : Ecnoglutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
Details : This U.S. phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics (biomarkers - FGF19 and C4) of ASC42 in healthy subjects. This trial also investigates the food effect on ASC42 exposure.
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2020
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable